A multi-institutional phase ii study of SU101, a platelet-derived growth factor receptor inhibitor, for patients with hormone-refractory prostate cancer.

@article{Ko2001AMP,
  title={A multi-institutional phase ii study of SU101, a platelet-derived growth factor receptor inhibitor, for patients with hormone-refractory prostate cancer.},
  author={Younghoon Ko and Eric Jay Small and Fairooz F. Kabbinavar and A. Chachoua and Samir S. Taneja and David Reese and Alexander Depaoli and Alison Campbell. Hannah and Steve P Balk and Glenn J. Bubley},
  journal={Clinical cancer research : an official journal of the American Association for Cancer Research},
  year={2001},
  volume={7 4},
  pages={
          800-5
        }
}
In a multi-institutional Phase II trial, we evaluated the efficacy of a platelet-derived growth factor receptor (PDGF-r) inhibitor, SU101, in patients with hormonerefractory prostate cancer. The patients received a 4-day i.v. loading dose of SU101 at 400 mg/m(2) for 4 consecutive days, followed by 10 weekly infusions at 400 mg/m(2). The primary study end points were a decline in prostate-specific antigen (PSA) and a decrease in measurable tumor. Secondary end points were time to progression and… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 63 CITATIONS

References

Publications referenced by this paper.
SHOWING 1-10 OF 12 REFERENCES

Similar Papers

Loading similar papers…